DDInter1215 DDInter899
Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome. The two marketed forms of mifepristone are Mifeprex® (mifepristone 200mg) and Korlym™ (mifepristone 300mg). Currently under investigation for use in psychotic depression (phase 3 trials).
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Mifepristone {u} (Compound) binds {v} (Gene) CYP3A5
Mifepristone {u} (Compound) upregulates {v} (Gene) CDK6
Mifepristone {u} (Compound) is included by {v} (Pharmacologic Class) Progestational Hormone Receptor Antagonists
Mifepristone {u} (Compound) downregulates {v} (Gene) ATP6V1D
Mifepristone {u} (Compound) causes {v} (Side Effect) Toxic shock syndrome
Mifepristone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Mifepristone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Mifepristone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naldemedine
Mifepristone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chloramphenicol
Mifepristone {u} may lead to a major life threatening interaction when taken with {v} Daunorubicin
Mifepristone (Compound) binds CYP3A5 (Gene)
Mifepristone (Compound) upregulates CDK6 (Gene)
Mifepristone (Compound) is included by Progestational Hormone Receptor Antagonists (Pharmacologic Class)
Mifepristone (Compound) downregulates ATP6V1D (Gene)
Mifepristone (Compound) causes Toxic shock syndrome (Side Effect)
Mifepristone may cause a minor interaction that can limit clinical effects when taken with Bexarotene
Mifepristone may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol
Mifepristone may lead to a major life threatening interaction when taken with Daunorubicin